From Rehabilitation Rooms to Everyday Steps: RoboCT’s Exoskeleton Bet
RoboCT, a Hangzhou-based company, is expanding its exoskeleton technology from clinical rehabilitation into broader consumer and outdoor mobility assistance markets, driven by a significant shift in China's exoskeleton market.
Intelligence analysis by Gemini 2.5 Flash
RoboCT, founded in 2017, initially focused on lower-limb rehabilitation exoskeletons, securing NMPA registrations in China. Now, with fresh capital, the company is pushing into the consumer market with products like the lightweight GoGo, aiming to bridge the gap between specialized medical devices and everyday wearable mobility tools.
Imagine if your legs sometimes felt too tired or weak to walk up stairs or go for a stroll, like after a really long day. A company called RoboCT makes special robot suits, called exoskeletons, that you can wear to give your legs a little boost. They started by helping people in hospitals get better, but now they're making lighter, simpler versions, like one called GoGo, so anyone who needs a bit of extra help can walk more easily outside, almost like having a superpower for your legs!
Analysis
RoboCT
RoboCT, established in 2017, has carved out a significant niche in the exoskeleton market, initially concentrating on lower-limb rehabilitation. The company's technological foundation is comprehensive, encompassing critical components such as motors, reducers, joint modules, sensors, and sophisticated control algorithms. This integrated approach allowed RoboCT to become an early entrant and secure NMPA registrations within China's regulated rehabilitation-device sector, underscoring its commitment to clinical efficacy and safety standards.
The development of rehabilitation exoskeletons by RoboCT goes beyond simple motorized braces; these devices are designed to be highly adaptable to individual patients and integrate seamlessly into therapist-led training protocols. The company's portfolio, as evidenced by a 2025 procurement award for Guangzhou University and a 2024 profile by the Chinese Association of Rehabilitation Medicine, includes various systems like lower-limb, seated/lying, and research exoskeletons, alongside a gait-analysis platform, showcasing its breadth in the medical field.
IDC’s 2026 report
According to IDC’s 2026 report on China’s 2025 exoskeleton market, the sector is undergoing a significant transformation, with an estimated market value exceeding RMB 1.6 billion and roughly 26,000 units shipped. This report positions medical rehabilitation as the primary driver of market value, while consumer-assistance devices are projected to account for over 70% of unit shipments, indicating a clear shift towards more accessible, multi-purpose wearable tools.
This market dynamic presents both opportunities and challenges for companies like RoboCT. The report highlights that while medical applications generate substantial revenue, the volume growth is in the consumer segment, suggesting a broader societal need for mobility assistance beyond clinical settings. RoboCT's strategy to span these segments—medical rehabilitation, consumer assistance, and industrial applications—is a direct response to this evolving market landscape, aiming to address diverse buyer groups as the market matures.
GoGo
RoboCT's foray into the consumer market is epitomized by its GoGo mobility-assistance exoskeleton, launched in July 2026. This product represents a deliberate pivot from the highly regulated clinical environment to everyday mobility, designed specifically for walking and outdoor use rather than formal gait therapy. The GoGo model is notably lightweight at approximately 2.3 kilograms and battery-free, utilizing a hip-mounted motor, making it practical for daily wear without clinical supervision.
This consumer push has been bolstered by significant financial backing, with RoboCT raising over RMB100 million in a Series B+ round in March 2026, led by ABC Capital. The capital infusion is earmarked for domestic and overseas expansion of consumer exoskeletons, R&D, registration of new brain-computer-interface products, and channel building. The success of GoGo and similar consumer devices will hinge on factors beyond just motor torque, including comfort, price, user training, and robust after-sales support, as the company navigates the complexities of mass-market adoption.
Key points
- RoboCT, founded in 2017, initially focused on lower-limb rehabilitation exoskeletons with NMPA registrations in China.
- China's exoskeleton market is projected to reach over RMB 1.6 billion by 2025, with consumer-assistance devices driving over 70% of unit shipments.
- RoboCT raised over RMB100 million in a Series B+ round in March 2026 to fund expansion into consumer and overseas markets, R&D, and new product registrations.
- The company launched its lightweight, battery-free GoGo mobility-assistance exoskeleton for outdoor and everyday use, marking its entry into the consumer market.
- RoboCT's strategy involves leveraging its core technology across medical, consumer, and industrial segments, but each requires distinct sales, safety, and service models.
RoboCT's expansion into consumer and overseas markets could significantly democratize access to assistive mobility technology, improving the quality of life for a wider population. Its diversified strategy across medical, consumer, and industrial applications positions it for robust growth as the exoskeleton market matures and broadens.
The transition from highly supervised clinical use to everyday consumer adoption presents substantial challenges, including ensuring comfort, managing price points, and providing adequate training and after-sales support. Failure to meet these consumer expectations could hinder widespread acceptance and sustained use of products like GoGo.
